Intrathecal tigecycline is a safe and effective treatment for central nervous system infections

Abstract

Both the safety and effectiveness of intrathecal tigecycline (TGC) for treatment of infections of the central nervous system (CNS) are discussed using the clinical findings from a study of a recent patient who came to our attention, along with a literature review. Although penetration into the CNS is low (approximately 11%), intraventricular TGC could help treat patients with severe post-neurosurgical CNS infections. The use of multiple routes of TGC administration appears to be encouraging and should be considered in managing life-threatening intraventricular infections.

Keywords

• tigecycline
• central nervous system bacterial infections
• intrathecal injections
• multi drug resistance